Commission Delegated Regulation (EU) 2024/2564

Contents

THE EUROPEAN COMMISSION,Having regard to the Treaty on the Functioning of the European Union,Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006^note, and in particular Article 37(5) thereof,Whereas:

(1)Part 3, Table 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.

(2)Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (‘the Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment (RAC) of the Agency adopted, after having taken account of the comments received from the parties concerned, the following opinions^note on those proposals:

—Opinion of 18 March 2022 concerning multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T;

—Opinion of 18 March 2022 concerning reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1] reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2];

—Opinion of 18 March 2022 concerning 2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol;

—Opinion of 30 May 2022 concerning glyphosate (ISO); N-(phosphonomethyl)glycine;

—Opinion of 2 June 2022 concerning silver massive: [particle diameter ≥ 1 mm];

—Opinion of 2 June 2022 concerning silver powder: [particle diameter > 100 nm < 1 mm];

—Opinion of 2 June 2022 concerning silver nano: [particle diameter > 1 nm ≤ 100 nm];

—Opinion of 2 June 2022 concerning S-metolachlor (ISO); 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide; (R_aS_a)-2-chloro-N-(6-ethyl-o-tolyl)-N-[(1S)-2-methoxy-1-methylethyl]acetamide [contains 80-100 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2R)-1-methoxypropan-2-yl]acetamide];

—Opinion of 2 June 2022 concerning 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one;

—Opinion of 2 June 2022 concerning formaldehyde … %;

—Opinion of 2 June 2022 concerning formic acid … %;

—Opinion of 18 March 2022 concerning α-methyl-1,3-benzodioxole-5-propionaldehyde [1] (S)-α-methyl-1,3-benzodioxole-5-propionaldehyde;(2S)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2] (R)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2R)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3];

—Opinion of 2 June 2022 concerning dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid;

—Opinion of 2 June 2022 concerning 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate;

—Opinion of 2 June 2022 concerning peracetic acid … %;

—Opinion of 2 June 2022 concerning tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy) ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1] Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotised 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2] disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3];

—Opinion of 15 September 2022 concerning perboric acid, sodium salt [1] perboric acid, sodium salt, monohydrate [2] perboric acid (HBO(O₂)), sodium salt, monohydrate [3] sodium peroxoborate [4] sodium perborate [5];

—Opinion of 15 September 2022 concerning perboric acid (H₃BO₂(O₂)), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O₂)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4]

—Opinion of 15 September 2022 concerning sodium peroxometaborate;

—Opinion of 15 September 2022 concerning trimethyl borate;

—Opinion of 15 September 2022 concerning ethanethiol;ethyl mercaptan;

—Opinion of 15 September 2022 concerning 1H-benzotriazole;

—Opinion of 18 March 2022 concerning acetone oxime;

—Opinion of 15 September 2022 concerning methyl-1H-benzotriazole;

—Opinion of 15 September 2022 concerning N,N'-methylenediacrylamide;

—Opinion of 15 September 2022 concerning Sodium 3-(allyloxy)-2-hydroxypropanesulphonate;

—Opinion of 1 December 2022 concerning tert-butyl 2-ethylperoxyhexanoate;

—Opinion of 1 December 2022 concerning n-hexane;

—Opinion of 1 December 2022 concerning biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl;

—Opinion of 1 December 2022 concerning copper [specific surface area > 0,67 mm²/mg];

—Opinion of 1 December 2022 concerning reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol;

—Opinion of 1 December 2022 concerning 1,4-dichloro-2-nitrobenzene;

—Opinion of 1 December 2022 concerning 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [1] (1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2] 2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3] 3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4] 3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5] 4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6] reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7] dimethylcyclohex-3-ene-1-carbaldehyde [8] Dimethylcyclohex-3-ene-1-carbaldehyde [9] 1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10] 1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11] 2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12] 2,4,6-trimethylcyclohex-3-enecarbaldehyde [13] isocyclocitral [14] 3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15] 4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16];

—Opinion of 18 March 2022 concerning (3E)-dec-3-en-2-one;

—Opinion of 1 December 2022 concerning pyraclostrobin (ISO); methyl N-(2-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxymethyl}phenyl) N-methoxy carbamate;

—Opinion of 1 December 2022 concerning dibenzoyl peroxide; benzoyl peroxide;

—Opinion of 1 December 2022 concerning fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine.

—Opinion of 18 March 2022 concerning 2,3-epoxypropyl neodecanoate;

—Opinion of 18 March 2022 concerning propyl 3,4,5-trihydroxybenzoate;

—Opinion of 18 March 2022 concerning benthiavalicarb-isopropyl (ISO); isopropyl [(S)-1-{[(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate;

—Opinion of 18 March 2022 concerning hexyl salicylate;

—Opinion of 18 March 2022 concerning sulfur;

(3)The Commission has received additional information from stakeholders contesting the scientific assessment set out in the RAC opinions of 18 March 2022 concerning benthiavalicarb-isopropyl, 2,3-epoxypropyl neodecanoate, multi-walled carbon tubes, hexyl salicylate, in the RAC opinions of 2 June 2022 concerning silver massive, silver powder and silver nano and in the RAC opinions of 1 December 2022 concerning n-hexane and copper. The additional information has been assessed by the Commission and has not been found sufficient to cast doubts on the scientific analysis contained in the RAC opinions.

(4)With regard to the substance copper flakes (coated with aliphatic acid) (index number 029-019-01-X^note), its entry for its classification as hazardous for the aquatic environment should be amended to be in accordance with the more generic entry copper [specific surface area > 0,67 mm²/mg] (index number 029-026-00-0), inserted in the Annex.

(5)With regard to the substance granulated copper^note (index number 029-024-00-X), its entry should be deleted as it is covered by the more generic entry copper [specific surface area > 0,67 mm²/mg] (index number 029-026-00-0), inserted in the Annex.

(6)Acute Toxicity Estimates (ATE) are mainly used to determine the classification for human health acute toxicity of mixtures containing substances classified for acute toxicity. The inclusion of harmonised ATE values in the entries listed in Annex VI to Regulation (EC) No 1272/2008 facilitates the harmonisation of the classification of mixtures and provides support for enforcement authorities. Following further scientific assessment, an ATE value for the inhalation route has been derived for fenpropidin (index number 612-299-00-0), in addition to those proposed in the RAC opinions for other substances. That ATE value should be inserted in the penultimate column of Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008.

(7)The entries corresponding to index numbers 005-017-00-7, 005-017-01-4, 005-018-00-2, 005-018-01-X, 005-019-00-8, 005-019-01-5 have been replaced by the entries for perboric acid, sodium salt [1] perboric acid, sodium salt, monohydrate [2] perboric acid (HBO(O2)), sodium salt, monohydrate [3] sodium peroxoborate [4] sodium perborate [5] (index number 005-022-00-4), for perboric acid (H3BO2(O2)), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4] (index number 005-023-00-X) and for sodium peroxometaborate (index number 005-024-00-5) and should therefore be deleted.

(8)In light of the RAC opinions, it is appropriate to introduce, update or delete the harmonised classification and labelling of the substances concerned on the basis of the assessment made in those opinions and following the further assessments.

(9)Regulation (EC) No 1272/2008 should therefore be amended accordingly.

(10)Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or updated classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation, to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers,

HAS ADOPTED THIS REGULATION:

Article 1 #

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Article 2 #

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.It shall apply from 1 May 2026 However, substances and mixtures may be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation from the date of entry into force of this Regulation.

(1)the following entries are inserted following the consecutive order of the index numbers corresponding to each entry:Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATE | NotesHazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)005-022-00-4 | perboric acid, sodium salt [1]perboric acid, sodium salt, monohydrate [2]perboric acid (HBO(O2)), sodium salt, monohydrate [3] sodium peroxoborate [4]sodium perborate [5] | 234-390-0 [1]234-390-0 [2]- [3]- [4]239-172-9 [5] | 11138-47-9 [1]12040-72-1 [2]10332-33-9 [3]- [4]15120-21-5 [5] | Ox. Sol. 3Repr. 1BAcute Tox. 3Acute Tox. 4STOT SE 3Eye Dam. 1 | H272H360FDH331H302H335H318 | GHS03GHS08GHS06GHS05Dgr | H272H360FDH331H302H335H318 | | inhalation: ATE = 0,75 mg/L (dusts or mists)oral: ATE = 890 mg/kg bwEye Dam. 1; H318:C ≥ 22 %Eye Irrit. 2; H319:14 % ≤ C < 22 % | 11005-023-00-X | perboric acid (H3BO2(O2)), monosodium salt trihydrate [1]perboric acid, sodium salt, tetrahydrate [2]perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4] | 239-172-9 [1]234-390-0 [2]- [3]- [4] | 13517-20-9 [1]37244-98-7 [2]10486-00-7 [3]- [4] | Repr. 1BAcute Tox. 4STOT SE 3Eye Dam. 1 | H360FDH332H335H318 | GHS08GHS05GHS07Dgr | H360FDH332H335H318 | | inhalation: ATE = 1,2 mg/L (dusts or mists)Eye Dam. 1; H318: C ≥ 36 %Eye Irrit. 2; H319: 22 % ≤ C < 36 % | 11005-024-00-5 | sodium peroxometaborate | 231-556-4 | 7632-04-4 | Ox. Sol. 2Repr. 1BAcute Tox. 3Acute Tox. 4STOT SE 3Eye Dam. 1 | H272H360FDH331H302H335H318 | GHS03GHS08GHS06GHS05Dgr | H272H360FDH331H302H335H318 | | inhalation: ATE = 0,62 mg/L (dusts or mists)oral: ATE = 730 mg/kg bwEye Dam. 1; H318:C ≥ 22 %Eye Irrit. 2; H319: 14 % ≤ C < 22 % | 11006-104-00-2 | multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T | — | — | Carc. 1BSTOT RE 1 | H350iH372 (lung)(inhalation) | GHS08Dgr | H350iH372 (lung)(inhalation) | | STOT RE 1; H372: C ≥ 1 %;STOT RE 2; H373: 0,1 % ≤ C < 1 % |029-026-00-0 | copper [specific surface area > 0,67 mm2/mg] | 231-159-6 | 7440-50-8 | Aquatic Acute 1Aquatic Chronic 1 | H400H410 | GHS09Wng | H410 | | M = 10M = 1 |047-004-00-9 | silver massive: [particle diameter ≥ 1 mm] | 231-131-3 | 7440-22-4 | Repr. 2STOT RE 2 | H361fH373 (nervous system) | GHS08Wng | H361fH373 (nervous system) | | |047-005-00-4 | silver powder: [particle diameter > 100 nm < 1 mm] | 231-131-3 | 7440-22-4 | Repr. 2STOT RE 2Aquatic Acute 1Aquatic Chronic 1 | H361fH373 (nervous system)H400H410 | GHS08GHS09Wng | H361fH373 (nervous system)H410 | | M = 10M = 10 |047-006-00-X | silver nano: [particle diameter > 1 nm ≤ 100 nm] | 231-131-3 | 7440-22-4 | Repr. 2STOT RE 2Aquatic Acute 1Aquatic Chronic 1 | H361fH373 (nervous system)H400H410 | GHS08GHS09Wng | H361fH373 (nervous system)H410 | | M = 1000M = 1000 |603-247-00-8 | reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol | — | — | Repr. 1B | H360Df | GHS08Dgr | H360Df | | |605-042-00-9 | α-methyl-1,3-benzodioxole-5-propionaldehyde [1](S)-α-methyl-1,3-benzodioxole-5-propionaldehyde;(2S)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2](R)-α-methyl-1,3-benzodioxole-5-propionaldehyde;(2R)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3] | 214-881-6 [1]- [2]- [3] | 1205-17-0 [1]737776-68-0 [2]737776-59-9 [3] | Skin Sens. 1B | H317 | GHS07Wng | H317 | | |605-043-00-4 | 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [1](1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2]2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3]3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4]3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5]4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6]reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7]dimethylcyclohex-3-ene-1-carbaldehyde [8]Dimethylcyclohex-3-ene-1-carbaldehyde [9]1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10]1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11]2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12]2,4,6-trimethylcyclohex-3-enecarbaldehyde [13]isocyclocitral [14]3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15]4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16] | 268-264-1 [1]252-395-6 [2]- [3]268-263-6 [4]267-186-5 [5]253-139-6 [6]- [7]248-742-6 [8]272-113-5 [9]276-055-1 [10]- [11]- [12]215-833-7 [13]215-638-7 [14]266-810-3 [15]- [16] | 68039-49-6 [1]35145-02-9 [2]6975-94-6 [3]68039-48-5 [4]67801-65-4 [5]36635-35-5 [6]- [7]27939-60-2 [8]68737-61-1 [9]71832-78-5 [10]40702-26-9 [11]1726-47-2 [12]1423-46-7 [13]1335-66-6 [14]67634-07-5 [15]6754-27-4 [16] | Skin Sens. 1 | H317 | GHS07Wng | H317 | | |606-156-00-1 | acetone oxime | 204-820-1 | 127-06-0 | Carc. 1BAcute Tox. 4STOT SE 3STOT RE 2Eye Dam. 1Skin Sens. 1 | H350H312H336H373 (blood system)H318H317 | GHS08GHS07GHS05Dgr | H350H312H336H373 (blood system)H318H317 | | dermal: ATE = 1100 mg/kg bw |606-157-00-7 | (3E)-dec-3-en-2-one | — | 18402-84-1 | Acute Tox. 4Asp. Tox. 1Skin Irrit. 2Aquatic Chronic 2 | H332H304H315H411 | GHS07GHS08GHS09Dgr | H332H304H315H411 | EUH071 | inhalation: ATE = 1,5 mg/L (dusts or mists) |606-158-00-2 | 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one | 438-340-0 | 119344-86-4 | Repr. 1BAquatic Acute 1Aquatic Chronic 1 | H360DfH400H410 | GHS08GHS09Dgr | H360DfH410 | | M = 1M = 1 |607-770-00-2 | 2,3-epoxypropyl neodecanoate | 247-979-2 | 26761-45-5 | Muta. 2Skin Sens. 1A | H341H317 | GHS08GHS07Wng | H341H317 | | Skin Sens. 1A; H317: C ≥ 0,001 % |607-771-00-8 | benthiavalicarb-isopropyl (ISO); isopropyl [(S)-1-{[(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate | — | 177406-68-7 | Carc. 1BRepr. 2Skin Sens. 1Aquatic Chronic 2 | H350H361fdH317H411 | GHS08GHS07GHS09Dgr | H350H361fdH317H411 | | |607-772-00-3 | hexyl salicylate | 228-408-6 | 6259-76-3 | Repr. 2Skin Sens. 1 | H361dH317 | GHS08GHS07Wng | H361dH317 | | |607-773-00-9 | 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate | 219-207-4 | 2386-87-0 | Muta. 2STOT RE 2Skin Sens. 1 | H341H373 (nasal cavity)H317 | GHS08GHS07Wng | H341H373 (nasal cavity)H317 | | |607-774-00-4 | tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy)ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1]Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotized 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2]disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3] | 241-164-5 [1]- [2]- [3] | 17095-24-8 [1]- [2]100556-82-9 [3] | Resp. Sens. 1ASkin Sens. 1 | H334H317 | GHS08Dgr | H334H317 | | |607-775-00-X | Sodium 3-(allyloxy)-2-hydroxypropanesulphonate | 258-004-5 | 52556-42-0 | Repr. 1BEye Dam. 1 | H360FH318 | GHS08GHS05Dgr | H360FH318 | | |609-074-00-4 | 1,4-dichloro-2-nitrobenzene | 201-923-3 | 89-61-2 | Carc. 1B | H350 | GHS08Dgr | H350 | | |611-182-00-1 | 2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol | 271-183-4 | 68516-81-4 | Skin Sens. 1A | H317 | GHS07Wng | H317 | | Skin Sens. 1A; H317: C ≥ 0,001 % |612-299-00-0 | fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine | — | 67306-00-7 | Repr. 2Acute Tox. 4Acute Tox. 4STOT SE 3STOT SE 3STOT RE 2Skin Irrit. 2Eye Dam. 1Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 | H361dH332H302H335H336H373 (nervous system, eyes, lungs)H315H318H317H400H410 | GHS08GHS07GHS05GHS09Dgr | H361dH332H302H335H336H373 (nervous system, eyes, lungs)H315H318H317H410 | | Inhalation: ATE = 1,2 mg/L (dusts or mists)oral: ATE = 1330 mg/kg bwM = 1000M = 10000 |613-350-00-X | 1H-benzotriazole | 202-394-1 | 95-14-7 | Aquatic Chronic 2 | H411 | GHS09Wng | H411 | | |613-351-00-5 | methyl-1H-benzotriazole | 249-596-6 | 29385-43-1 | Aquatic Chronic 2 | H411 | GHS09Wng | H411 | | |616-243-00-6 | N,N'-methylenediacrylamide | 203-750-9 | 110-26-9 | Muta. 1B | H340 | GHS08Dgr | H340 | | |617-024-00-8 | tert-butyl 2-ethylperoxyhexanoate | 221-110-7 | 3006-82-4 | Repr. 1BSkin Sens. 1 | H360FDH317 | GHS08GHS07Dgr | H360FDH317 | | |

(2)the entries corresponding to index numbers 005-005-00-1, 016-022-00-9, 016-094-00-1, 029-019-01-X, 601-037-00-0, 604-020-00-6, 605-001-00-5, 607-001-00-0, 607-043-00-X, 607-094-00-8, 607-198-00-3, 607-315-00-8, 607-432-00-4, 613-272-00-6, 616-127-00-5 and 617-008-00-0 are replaced by the following entries respectively:Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATE | NotesHazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)005-005-00-1 | trimethyl borate | 204-468-9 | 121-43-7 | Flam. Liq. 3Repr. 1BAcute Tox. 4* | H226H360FDH312 | GHS02GHS08GHS07Dgr | H226H360FDH312 | | | 11016-022-00-9 | ethanethiol;ethyl mercaptan | 200-837-3 | 75-08-1 | Flam. Liq. 1Acute Tox. 3Acute Tox. 4Aquatic Acute 1Aquatic Chronic 1 | H224H331H302H400H410 | GHS02GHS06GHS09Dgr | H224H331H302H410 | | inhalation: ATE = 7,1 mg/L (vapours)oral: ATE = 680 mg/kg bw |016-094-00-1 | sulfur | 231-722-6 | 7704-34-9 | Skin Irrit. 2 | H315 | GHS07Wng | H315 | | |029-019-01-X | copper flakes (coated with aliphatic acid) | | | Acute Tox. 3 Acute Tox. 4Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H331H302H319H400H410 | GHS06GHS09Dgr | H331H302H319H410 | | inhalation: ATE = 0,733 mg/l (dusts or mists)oral: ATE = 500 mg/kg bwM = 10M = 1 |601-037-00-0 | n-hexane | 203-777-6 | 110-54-3 | Flam. Liq. 2Repr. 2Asp. Tox. 1STOT SE 3STOT RE 1Skin Irrit. 2Aquatic Chronic 2 | H225H361f***H304H336H372 (nervous system)H315H411 | GHS02GHS08GHS07GHS09Dgr | H225H361f***H304H336H372 (nervous system)H315H411 | | |604-020-00-6 | biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl | 201-993-5 | 90-43-7 | Carc. 2Skin Corr. 1Eye Dam. 1Skin Sens. 1BAquatic Acute 1Aquatic Chronic 1 | H351H314H318H317H400H410 | GHS08GHS05GHS07GHS09Dgr | H351H314H317H410 | | M = 1M = 1 |605-001-00-5 | formaldehyde … % | 200-001-8 | 50-00-0 | Carc. 1BMuta. 2Acute Tox. 2Acute Tox. 4Skin Corr. 1BSkin Sens. 1A | H350H341H330H302H314H317 | GHS08GHS06GHS05Dgr | H350H341H330H302H314H317 | EUH071 | inhalation: ATE = 100 ppmV (gases)oral: ATE = 500 mg/kg bwSTOT SE 3; H335: C ≥ 5 %Skin Corr. 1B; H314: C ≥ 25 %Skin Irrit. 2; H315: 5 % ≤ C < 25 %Eye Irrit. 2; H319: 5 % ≤ C < 25 % | B, D, F607-001-00-0 | formic acid … % | 200-579-1 | 64-18-6 | Flam. Liq. 3Met. Corr. 1Acute Tox. 3Acute Tox. 4Skin Corr. 1AEye Dam. 1 | H226H290H331H302H314H318 | GHS02GHS05GHS06Dgr | H226H290H331H302H314 | EUH071 | inhalation: ATE = 7,4 mg/L (vapours)oral: ATE = 500 mg/kg bwFlam. Liq. 3; H226: C > 85 %Skin Corr. 1A; H314: C ≥ 90 %Skin Corr. 1B; 314: 10 % ≤ C < 90 %Skin Irrit. 2; H315: 2 % ≤ C < 10 %Eye Dam. 1; H318: C ≥ 10 %Eye Irrit. 2; H319: 2 % ≤ C < 10 % | B607-043-00-X | dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid | 217-635-6 | 1918-00-9 | Acute Tox. 4Acute Tox. 4STOT SE 3STOT SE 3Eye Dam. 1Aquatic Acute 1Aquatic Chronic 2 | H332H302H335H336H318H400H411 | GHS07GHS05GHS09Dgr | H332H302H335H336H318H410 | | inhalation: ATE = 4,0 mg/L (dusts or mists)oral: ATE = 1500 mg/kg bwM = 1 |607-094-00-8 | peracetic acid … % | 201-186-8 | 79-21-0 | Org. Perox. DAcute Tox. 2Acute Tox. 2Acute Tox. 3Skin Corr. 1AAquatic Acute 1Aquatic Chronic 1 | H242H330H310H301H314H400H410 | GHS02GHS06GHS05GHS09Dgr | H242H330H310H301H314H410 | EUH071 | inhalation: ATE = 0,2 mg/L (dusts or mists)dermal: ATE = 60 mg/kg bworal: ATE = 80 mg/kg bwSTOT SE 3; H335: C ≥ 1 %M = 10M = 100 | B, D, T607-198-00-3 | propyl 3,4,5-trihydroxybenzoate | 204-498-2 | 121-79-9 | Acute Tox. 4Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 | H302H317H400H410 | GHS07GHS09Wng | H302H317H410 | | oral: ATE = 1700 mg/kg bwM = 1M = 1 |607-315-00-8 | glyphosate (ISO); N-(phosphonomethyl)glycine | 213-997-4 | 1071-83-6 | Eye Dam. 1Aquatic Chronic 2 | H318H411 | GHS05GHS09Dgr | H318H411 | | |607-432-00-4 | S-metolachlor (ISO); 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide; (RaSa)-2-chloro-N-(6-ethyl-o-tolyl)-N-[(1S)-2-methoxy-1-methylethyl]acetamide[contains 80-100 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2R)-1-methoxypropan-2-yl]acetamide] | — | 87392-12-9 | Carc. 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 | H351H317H400H410 | GHS08GHS07GHS09Wng | H351H317H410 | EUH066 | M = 10M = 10 |613-272-00-6 | pyraclostrobin (ISO); methyl N-(2-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxymethyl}phenyl) N-methoxy carbamate | — | 175013-18-0 | Repr. 2Acute Tox. 3Acute Tox. 4STOT SE 3STOT RE 2Skin Irrit. 2Aquatic Acute 1Aquatic Chronic 1 | H361dH331H302H335H373 (liver, gastrointestinal tract, nasal cavity)H315H400H410 | GHS08GHS06GHS09Dgr | H361dH331H302H335H373 (liver, gastrointestinal tract, nasal cavity)H315H410 | | inhalation: ATE = 0,58 mg/L (dusts or mists)oral: ATE = 450 mg/kg bwM = 100M = 100 |616-127-00-5 | reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1]reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2] | 430-050-2 [1]- [2] | - [1]- [2] | Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 | H317H400H410 | GHS07GHS09Wng | H317H410 | | M = 100M = 10 |617-008-00-0 | dibenzoyl peroxide; benzoyl peroxide | 202-327-6 | 94-36-0 | Org. Perox. BEye Irrit. 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 | H241H319H317H400H410 | GHS01GHS02GHS07GHS09Dgr | H241H319H317H410 | | M = 10M = 10 |

(3)the entries corresponding to index numbers 005-017-00-7, 005-017-01-4, 005-018-00-2, 005-018-01-X, 005-019-00-8, 005-019-01-5 and 029-024-00-X are deleted.

Part 3, Table 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

Article 1#

Article 2#

Article 1 #

Article 2 #